Safety, Pharmacokinetics, and Antiviral Activity of the Next-Generation Hepatitis B Capsid Assembly Modulator ABI-4334 in Patients With HBeAg-Negative Chronic Hepatitis B Infection Not Suppressed on Nucleoside Analogues: Results From a Randomized, Blinded, Phase 1b Study

Conference Reports for NATAP

The Liver Meeting
AASLD 2025
Washington, D.C.
November 7-11, 2025


Safety, Pharmacokinetics, and Antiviral Activity of the Next-Generation Hepatitis B Capsid Assembly Modulator ABI-4334 in Patients With HBeAg-Negative Chronic Hepatitis B Infection Not Suppressed on Nucleoside Analogues: Results From a Randomized, Blinded, Phase 1b Study

	AASLD Nov 2025 HBV at AASLD 2025 AASLD: What Are the Major Barriers to Hepatitis B Elimination and How to Overcome Them, Expanded AASLD HBV Guidelines - (11/24/25) AASLD: The Dawn of a Cure for HBV, HBV Drug Pipeline - (11/24/25) Alina Jucov1, Nelli Ghicavii2, Ran Yan3, Kathryn M Kitrinos3, Jieming Liu3, Katie Zomorodi3, Steven J Knox3, Anuj Gaggar3, Grace Wang3, Edward J Gane4 1ARENSIA Exploratory Medicine GmbH, Düsseldorf, Germany and Department of Gastroenterology, State University of Medicine and Pharmacy, Chisinau, Republic of Moldova; 2ARENSIA Exploratory Medicine GmbH, Republican Clinical Hospital, Chisinau, Republic of Moldova; 3Assembly Biosciences, South San Francisco, CA, USA; 4University of Auckland, Auckland, New Zealand